Target Validation in Drug Discovery

Edited by

  • Brian Metcalf, Chief Drug Discovery Officer, Incyte Corporation, Moraga, CA, U.S.A.
  • Susan Dillon, Senior Vice President, Discovery Research Centocor, Johnson & Johnson, Malvern, PA, U.S.A.

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
View full description


Professionals in biotechnology and pharmaceutical drug discovery and clinical development. Can also include students and academics in the related areas of study.


Book information

  • Published: September 2006
  • ISBN: 978-0-12-369393-8

Table of Contents

Section ContentsI. Pharmaceutical Biotechnology for Target ValidationII. Target Validation for Biopharmaceutical Drug DiscoveryIII. Validating Targets of Small Molecule Approaches